Want to see NDRA full AI Analyst Report?
NDRA Stock Chart & Stats
$4.75
-$0.08(-1.65%)
At close: 4:00 PM EDT
$4.75
-$0.08(-1.65%)
Day’s Range― - ―
52-Week Range$2.96 - $9.85
Previous Close$4.78
Volume5.95K
Average Volume (3M)44.01K
Market Cap
$8.25M
Enterprise Value$1.95
Total Cash (Recent Filing)$1.74M
Total Debt (Recent Filing)$429.27K
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Nov 16, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.33
Shares Outstanding1,499,838
10 Day Avg. Volume48,393
30 Day Avg. Volume44,012
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.58
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits near-term solvency pressure and reduces the burden of interest and refinancing obligations. This gives ENDRA more financial flexibility than a similarly loss-making company, although its ability to sustain operations still depends on securing funding.
Narrowing LossesThe steady reduction in reported losses indicates some progress in controlling the cost base and may improve capital efficiency over time. If maintained, this trend could extend the company’s operating runway and reduce the amount of external funding required before commercialization.
Potential Strategic FundingA proposed $50 million capital raise could provide substantial resources for development and support the post-transaction company’s capital needs. If the merger and financing close, the funding may materially strengthen execution capacity compared with ENDRA’s current cash-burning position.
Bears Say
No Revenue TractionPersistent zero revenue shows that ENDRA has not yet demonstrated commercial adoption of its imaging platform. Without product sales or recurring service income, the business lacks an operating revenue base to absorb expenses, validate demand, or support internally funded growth.
Persistent Cash BurnMaterial operating and free-cash-flow deficits indicate that ENDRA cannot currently fund its activities from operations. Continued burn increases reliance on equity raises or other financing, potentially constraining strategy and creating ongoing funding risk over the next several quarters.
Merger Execution And Control RiskThe proposed transformation away from the legacy imaging business depends on multiple approvals, financing conditions and transaction milestones. If completed, ASP Isotopes’ effective control and Noble-dominated governance would also leave existing ENDRA holders with limited influence over strategic decisions.
ENDRA Life Sciences News
NDRA FAQ
What was ENDRA Life Sciences Inc’s price range in the past 12 months?
ENDRA Life Sciences Inc lowest stock price was $2.96 and its highest was $9.85 in the past 12 months.
What is ENDRA Life Sciences Inc’s market cap?
ENDRA Life Sciences Inc’s market cap is $8.25M.
When is ENDRA Life Sciences Inc’s upcoming earnings report date?
ENDRA Life Sciences Inc’s upcoming earnings report date is Nov 16, 2026 which is in 56 days.
How were ENDRA Life Sciences Inc’s earnings last quarter?
ENDRA Life Sciences Inc released its earnings results on Aug 17, 2026. The company reported $0.121 earnings per share for the quarter, beating the consensus estimate of -$0.84 by $0.961.
Is ENDRA Life Sciences Inc overvalued?
According to Wall Street analysts ENDRA Life Sciences Inc’s price is currently Overvalued.
Does ENDRA Life Sciences Inc pay dividends?
ENDRA Life Sciences Inc does not currently pay dividends.
What is ENDRA Life Sciences Inc’s EPS estimate?
ENDRA Life Sciences Inc’s EPS estimate is -0.84.
How many shares outstanding does ENDRA Life Sciences Inc have?
ENDRA Life Sciences Inc has 1,499,838 shares outstanding.
What happened to ENDRA Life Sciences Inc’s price movement after its last earnings report?
ENDRA Life Sciences Inc reported an EPS of $0.121 in its last earnings report, beating expectations of -$0.84. Following the earnings report the stock price went up 0.447%.
Which hedge fund is a major shareholder of ENDRA Life Sciences Inc?
Currently, no hedge funds are holding shares in NDRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
Technical Analysis
Ownership Overview
26.90% Insiders
0.70% Mutual Funds
5.85% Other Institutional Investors
66.07% Public Companies and
Individual Investors